218 related articles for article (PubMed ID: 10705470)
1. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
[TBL] [Abstract][Full Text] [Related]
4. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.
Matsuhisa A; Koshio H; Sakamoto K; Taniguchi N; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1566-79. PubMed ID: 9810694
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
[TBL] [Abstract][Full Text] [Related]
9. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
Risvanis J; Naitoh M; Johnston CI; Burrell LM
Eur J Pharmacol; 1999 Sep; 381(1):23-30. PubMed ID: 10528130
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.
Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tokioka T; Uchida W; Inagaki O; Iizumi Y; Tanaka A; Honda K
Eur J Pharmacol; 1999 Jul; 376(3):239-46. PubMed ID: 10448882
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
14. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
[TBL] [Abstract][Full Text] [Related]
16. Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.
Yatsu T; Kusayama T; Tomura Y; Arai Y; Aoki M; Tahara A; Wada K; Tsukada J
Pharmacol Res; 2002 Nov; 46(5):375-81. PubMed ID: 12419640
[TBL] [Abstract][Full Text] [Related]
17. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
[TBL] [Abstract][Full Text] [Related]
18. Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Peptides; 1998; 19(4):691-6. PubMed ID: 9622024
[TBL] [Abstract][Full Text] [Related]
19. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
20. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
Wada K; Tahara A; Arai Y; Aoki M; Tomura Y; Tsukada J; Yatsu T
Eur J Pharmacol; 2002 Aug; 450(2):169-77. PubMed ID: 12206855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
